Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals

Advances in Therapy

Volumn 28, Issue 4, 2011, Pages 326-333

  Eagye, Kathryn J ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobial resistance; Fluoroquinolones; Imipenem; Pseudomonas aeruginosa

Indexed keywords

CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANALYSIS OF VARIANCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG USE; HOSPITAL BED CAPACITY; MEDICAL RESEARCH; NONHUMAN; PSEUDOMONAS AERUGINOSA; TEACHING HOSPITAL;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HOSPITALS, TEACHING; HUMANS; IMIPENEM; INFECTION CONTROL; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 79958217987     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0010-8     Document Type: Article

References (22)

1. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006;27:893-900. (Pubitemid 44449245)
2. Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review. BMC Pulm Med. 2010;10:45.
3. Thabet L, Memmi M, Turki A, Messadi AA. The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department. Tunis Med. 2010;88:696-699.
4. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother. 2009;43:220-227.
5. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999;159:1127-1132. (Pubitemid 29230866)
6. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis. 2002;34:340-345. (Pubitemid 34062234)
7. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379-1382. (Pubitemid 29259329)
8. Leroy O, d'Escrivan T, Devos P, Dubreuil L, Kipnis E, Georges H. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection. 2005;33:129-135.
9. Cambau E, Perani E, Dib C, Petinon C, Trias J, Jarlier V. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother. 1995;39:2248-2252.
10. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenemresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:1983-1986.
11. Mueller MR, Hayden MK, Fridkin SK. et al. Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis. Eur J Clin Microbiol Infect Dis. 2008;27:565-570.
12. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol. 2010;31:485-490.
13. Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect. 2005;11:4-16. (Pubitemid 41341707)
14. Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006;64:7-15. (Pubitemid 44161380)
15. Paramythiotou E, Lucet JC, Timsit JF. et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. 2004;38:670-677. (Pubitemid 38333863)
16. WHOCC ATC/DDD Index 2011. Available at: http://www.whocc.no/atcddd/. Accessed June 1, 2009.
17. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat Rev Microbiol. 2004;2:979-983.
18. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-485.
19. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med. 2003;24:121-134.
20. Rosenthal VD, Maki DG, Mehta A. et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control. 2008;36:627-637.
21. Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin Ther. 2009;31:2678-2688.
22. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007;44:664-670.